Trial · NCT04977336
Results by group71
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 71
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug | Placebo | 100.98 | Standard Error 11.60 | units on a scale | |
| Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug | HB/APAP | 115.64 | Standard Error 11.49 | units on a scale | |
| Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug | VX-548: Low Dose | 112.92 | Standard Error 15.52 | units on a scale | |
| Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug | VX-548: Mid Dose | 86.87 | Standard Error 11.33 | units on a scale | |
| Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug | VX-548: High Dose | 137.77 | Standard Error 11.50 | units on a scale | |
| Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug | Placebo | 31.54 | Standard Error 5.57 | units on a scale | |
| Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug | HB/APAP | 40.95 | Standard Error 5.52 | units on a scale | |
| Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug | VX-548: Low Dose | 34.36 | Standard Error 7.45 | units on a scale | |
| Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug | VX-548: Mid Dose | 24.78 | Standard Error 5.44 | units on a scale | |
| Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug | VX-548: High Dose | 45.22 | Standard Error 5.52 | units on a scale | |
| Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug | Placebo | 67.8 | percentage of participants | ||
| Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug | HB/APAP | 68.3 | percentage of participants | ||
| Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug | VX-548: Low Dose | 75.8 | percentage of participants | ||
| Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug | VX-548: Mid Dose | 62.9 | percentage of participants | ||
| Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug | VX-548: High Dose | 83.3 | percentage of participants | ||
| Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug | Placebo | 61.0 | percentage of participants | ||
| Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug | HB/APAP | 61.7 | percentage of participants | ||
| Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug | VX-548: Low Dose | 72.7 | percentage of participants | ||
| Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug | VX-548: Mid Dose | 56.5 | percentage of participants | ||
| Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug | VX-548: High Dose | 66.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04977336/results